Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab

In neuromyelitis optica (NMO), the monoclonal B-cell antibody
rituximab is a therapeutic option. Little is known about the course
of NMO and the safety of rituximab during pregnancy. In this study,
we report the clinical course of a patient with NMO after
application of rituximab 1 week before inadvertent conception.
Mother and child did not experience any adverse event, and the
postpartum development of the baby was completely normal up to 15
months. Clinical course of NMO was stable during the entire
pregnancy. This case illustrates a favorable outcome in a pregnant
NMO patient and her child after therapy with rituximab.